Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **hyaluronic acid** (a glycosaminoglycan used as a dermal filler for soft tissue augmentation) and **botulinum toxin type A** (a neurotoxin protein that inhibits acetylcholine release at neuromuscular junctions), delivered together via injection for aesthetic and dermatological purposes, primarily **facial rejuvenation** (wrinkle reduction, skin texture and pore improvement). The combination leverages the muscle-relaxing action of botulinum toxin type A, which temporarily reduces dynamic wrinkles by blocking neuromuscular transmission, and the hydrating, volumizing, and skin-structural benefits of hyaluronic acid, which fills static wrinkles and restores facial volume. Studies consistently report **greater efficacy, longer duration of effect, smaller toxin doses, and improved patient satisfaction** compared to the use of either agent alone. The treatment is widely used in aesthetic medicine for facial rejuvenation, wrinkle reduction, and for improving acne-associated enlarged pores[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + botulinum toxin type A.